Efficacy of Maternal Influenza Vaccination Against All-Cause Lower Respiratory Tract Infection Hospitalizations in Young Infants: Results From a Randomized Controlled Trial영아의 모든 원인 하기도 감염 입원에 대한 산모 인플루엔자 예방 접종의 효능: 무작위 대조 시험의 결과Articles and Commentaries Published on 2017-10-012022-09-06 Journal: Clinical Infectious Diseases: An Official Publicat [Category] Communicable Disease, [키워드] Against age Analysis Bacterial infection Bacterial infections benefit clinical confidence interval Controlled double-blind during pregnancy Efficacy evaluated Hospitalization hospitalizations Hospitalized immunization inactivated incidence incidence rate infancy Infant Infants Infection Influenza influenza infection influenza vaccination influenza vaccine Influenza virus laboratory-confirmed life Lower Lower respiratory tract lower respiratory tract infection lower respiratory tract infections Maternal median age occurred participated phase 3 trial placebo group placebo recipient placebo recipients placebo-controlled positive Pregnancy pregnant women probe PROTECT randomized clinical trial rate ratio RCT recipient Registration respiratory Result severe pneumonia subsequent tested the placebo group tract trivalent vaccination Vaccine vaccine efficacy virus infection women [DOI] 10.1093/cid/cix497 PMC 바로가기 [Article Type] Articles and Commentaries
Safety and immunogenicity of a parenteral P2-VP8-P[8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double-blind, placebo-controlled trial남아프리카 공화국의 유아 및 유아에 대한 비경구 P2-VP8-P[8] 서브유닛 로타바이러스 백신의 안전성 및 면역원성: 무작위, 이중 맹검, 위약 대조 시험Articles Published on 2017-05-052022-09-06 Journal: The Lancet. Infectious Diseases [Category] Communicable Disease, [키워드] 95% CI adjusted adverse event adverse events African approach assigned benefit block Block randomisation Cohort computer-generated different dose different doses dose dose-escalation doses double-blind eligible Endpoint enrolled finding FIVE followed by foundation Frequency funding geometric mean geometric mean titre geometric mean titres groups healthy highest HIV-uninfected homologous hospital IgA IgG IgG seroresponse immunogenic immunogenicity Infant Infants injection Injections Laboratory live oral rotavirus vaccines Local Melinda Gate Melinda Gates Mild neutralising antibody neutralising antibody seroresponse neutralising antibody seroresponses nine non-replicating rotavirus vaccine occurred offer oral rotavirus vaccine oral vaccines parent Parenteral parents participant Placebo placebo group placebo-controlled placebo-controlled trial primary immunogenicity randomisation randomised reaction receiving reduced Registered Research rotavirus rotavirus disease rotavirus vaccination rotavirus vaccine Safety safety analysis safety endpoint Serious Adverse Event Serious Adverse Events Serum IgA seroresponse Serum IgA seroresponses Seven severity South South Africa subunit Subunit vaccine systemic reaction systemic reactions the placebo group those receiving placebo Treatment Trial trivalent vaccination Vaccine was done was used [DOI] 10.1016/S1473-3099(17)30242-6 PMC 바로가기 [Article Type] Articles
Randomized, double-blind, placebo-controlled clinical trial to assess the safety and effectiveness of a novel dual-action oral topical formulation against upper respiratory infectionsResearch Article Published on 2017-01-142022-10-28 Journal: BMC Infectious Diseases [Category] Coronavirus, MERS, [키워드] age antimicrobial agent Antiviral ARMS Barrier formation cetylpyridinium chloride clinical trial Comparisons component conducted Contact coronavirus cough current demonstrated double-blind double-blinded Effectiveness Efficacy enrolled evaluate Frequency Glycerin had no Host individual Influenza Invasion medication mucosa not differ not significant occurred outcome pilot clinical trial placebo group placebo-controlled placebo-controlled clinical trial proof-of-concept clinical trial Prophylaxis Randomized reduced reducing reduction Registered reported representing Result rhinovirus Safe Secondary objective severity significantly sore throat statistically study outcomes study participant Study participants subject supplementary material the placebo group Tolerability treatment of influenza upper respiratory infection vaccination virus detection was reduced Xanthan gum [DOI] 10.1186/s12879-016-2177-8 PMC 바로가기 [Article Type] Research Article
Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trialHIV-1에 감염된 건강한 성인에서 후보 결핵 백신 MVA85A의 안전성, 면역원성 및 효능: 무작위, 위약 대조, 2상 시험Articles Published on 2015-03-012022-09-06 Journal: The Lancet. Respiratory Medicine [Category] Communicable Disease, [키워드] 1:1 95% CI absence active tuberculosis adverse event Antigen antigen 85A antigen 85A-specific T-cell response antiretroviral Antiretroviral therapy assigned assist baseline baseline CD4 block blocks booster Cape CD4 count CD4 counts Cell clinical defined detect detectable Developing disease double-blind effective Efficacy eligible Eligible participants enrolled enrolment European Evidence evidence of expressing finding first vaccination foundation funding gold greater Group allocation had no healthy HIV-1 HIV-1 infection immunogenic immunogenicity include increased risk Infection injection intradermal injections investigators isoniazid isoniazid prophylaxis Laboratory latent tuberculosis latent tuberculosis infection M tuberculosis Measures Melinda Gate Melinda Gates modified vaccinia virus MVA85A Mycobacterium tuberculosis nine no evidence of Nurses occurred outcome participant partnership peaked per-protocol analysis per-protocol population Phase 2 phase 2 trial Placebo placebo group placebo-controlled positive Potential Prophylaxis protocol QuantiFERON QuantiFERON-TB Gold In-Tube randomisation randomised Randomly receive receiving Registered reported Safe Safety safety analysis second vaccination secondary Secondary outcomes sequence Serious Adverse Event Serious Adverse Events significant increase South Africa stratified subset T-cell Response the placebo group therapy town Treatment Trial Tuberculosis tuberculosis disease tuberculosis vaccine undetectable vaccination Vaccine vaccine efficacy vaccine-induced immune response Viral Viral load Wellcome Trust were assessed [DOI] 10.1016/S2213-2600(15)00037-5 PMC 바로가기 [Article Type] Articles